Get a prescription for Wegovy online in Canada

Wegovy is a prescription medication containing semaglutide. In Canada, it is authorized for chronic weight management in eligible adults with obesity, or adults who are overweight and have at least one weight-related health condition, alongside a reduced-calorie diet and increased physical activity.

Wegovy works through the GLP-1 pathway, which can affect appetite and feelings of fullness. A healthcare provider can determine whether Wegovy is appropriate based on your health history, current medications, and weight-management goals.

Wegovy can support your weight management efforts by mimicking a natural gut hormone called GLP-1. It signals your brain to reduce hunger and can decrease cravings over time. GLP-1 medications lower how much you want to eat, so alongside changes to nutrition and physical activity, Wegovy can enable significant weight loss.

Weight loss results with Wegovy vary from person to person. Clinical studies suggest an average loss of around 5–15% of body weight over several months, though individual results differ. Phoenix patients report losing an average of 8.9 pounds in the first month of weight loss treatment. 

Factors like your Wegovy dosage, starting weight, how consistently you take it, and the lifestyle changes you make all play a role. Most people do see weight changes, especially as the dose increases over time. A licensed healthcare provider can help set realistic expectations for weight management on Wegovy.

When starting Wegovy, some people notice appetite changes within the first few weeks. Weight loss usually happens after 2 to 3 months, particularly after you move to a higher dose, and results can continue over 6 to 12 months of consistent use. 

It’s important to follow your provider's guidance on when to take Wegovy and how to adjust your schedule.

The most common Wegovy side effects are nausea, vomiting, diarrhea, constipation, and stomach discomfort. These tend to occur during the early weeks or after a dose increase. Eating smaller meals, chewing slowly, and avoiding greasy or rich foods can help.

For most people, side effects improve as the body adjusts to the semaglutide. Some people need a slower dose escalation to manage them. Severe or persistent abdominal pain should always be evaluated by a medical professional right away. If you have concerns about the side effects of Wegovy, a licensed healthcare provider is the best resource.

If you stop Wegovy, blood sugar control can worsen if you have type 2 diabetes. Appetite typically returns to its previous level, and weight regain is common if eating and activity habits have not changed. 

Never stop or change your Wegovy dose without talking to your provider first. They will create a plan that protects your health whether you continue, pause, or switch medications.

How to inject Wegovy: This treatment comes as a pre-filled Wegovy pen designed for subcutaneous (under-the-skin) injection. Common Wegovy injection sites include the abdomen, thigh, or upper arm. Rotate your injection site each week to reduce irritation.

Wegovy pen instructions: Remove the cap, dial to your prescribed Wegovy dose, and inject at a 90-degree angle. Full Wegovy injection instructions are included in the package insert.

Wegovy dosing schedule: The standard Wegovy administration schedule is once weekly, on the same day each week. Wegovy strength comes in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg doses, usually starting with a low dose and increasing gradually.

How to store Wegovy: Wegovy refrigeration is required before first use. Store unopened pens in the refrigerator between 2°C and 8°C (36°F and 46°F). After first use, Wegovy pen storage allows you to keep the pen at room temperature (up to 25°C / 77°F) for up to 56 days. Store Wegovy away from direct heat and sunlight. Never freeze the pen, and always put the cap back on after each use.

Wegovy vs. Mounjaro: Mounjaro is a tirzepatide medication that targets both GLP-1 and GIP receptors, while Wegovy is a semaglutide medication that targets GLP-1 only. This difference in the mechanism of action may lead to different weight loss outcomes for different people.

Wegovy vs. Rybelsus: Rybelsus contains the same active ingredient, semaglutide, but comes in a daily oral tablet rather than a weekly injection. The doses offered are also different. 

Talk to a licensed healthcare provider about which option makes sense for your health goals.